别名 D11S833E、GARP、Garpin + [5] |
简介 Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space (PubMed:19750484, PubMed:19651619, PubMed:22278742). Associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGF-beta, and regulates integrin-dependent activation of TGF-beta (PubMed:22278742). Able to outcompete LTBP1 for binding to LAP regulatory chain of TGF-beta (PubMed:22278742). Controls activation of TGF-beta-1 (TGFB1) on the surface of activated regulatory T-cells (Tregs) (PubMed:19750484, PubMed:19651619). Required for epithelial fusion during palate development by regulating activation of TGF-beta-3 (TGFB3) (By similarity). |
作用机制 LRRC32调节剂 [+1] |
在研机构 |
非在研适应症- |
最高研发阶段临床2/3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 LRRC32 抑制剂 [+1] |
在研适应症 |
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 LRRC32调节剂 |
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-04-30 |
申办/合作机构 |
开始日期2024-04-18 |
申办/合作机构 上海复宏汉霖生物制药有限公司 [+1] |
开始日期2024-04-16 |
申办/合作机构 |